
Opening session
- Gilles Toulemonde CEO @ Inpart
The introduction to the Summit from Gilles Toulemonde, CEO of Inpart, introduced Inpart’s advancements in partnering automation and activating scientific networks, help companies streamline operations and establish best practices.
HIGHLIGHTS
- - Welcome and Introduction
- - The evolution of Innovation
- - UGM Goals
- - Inpart's Innovation Focus
- - Post-COVID Reflections
Key talking points
Welcome and Introduction
Gilles welcomed attendees to Lyon, highlighting the city’s rich history in medical innovation.
Evolution of Innovation
Gilles outlined the shift from individual innovation in medicine to a more fragmented ecosystem now, with biotechs and research institutions leading invention, and large pharma acting as catalysts.
UGM Goals
Gilles set the context for the User Group Meeting (UGM), emphasizing the need to share best practices in BD and alliance management, and the importance of collaboration and feedback in shaping Inpart’s innovation journey.
Organizational Growth
He mentioned Inpart’s growth, with a larger customer base and the release of the new Deal platform, inviting feedback on its utility.
Acknowledgments
Gilles finished by thanking the Top 50 pharma companies attending, including AstraZeneca, GSK, CSL, and others, and praised the organizing team behind the UGM.
Continue watching
Enabling successful teams
Explore strategies helping build cultures of excellence and innovation within top biopharma companies, establishing new best practices enabling teams across an organization to deliver successful partnering, discovery, and development.
- Alyson Joyce BD Operations @ Servier
- Jean Baptiste de Peretti Senior Manager @ Ipsen
- Arun S. Bisht Head of Excellence and Operations @ Novartis
Partnering 2030 & Top Pharma rankings
The session introduced the Partnering 2030 program, covering the key findings, and top pharma rankings for 2024.
- Sarah Issa Chief Marketing Officer @ Inpart
Sourcing the best science
This session featured presentations on best practices for sourcing early and late-stage science, the value of maintaining strong relationships, and tailored approaches to keeping diverse partners satisfied. It also reviewed the latest digital tools for optimal sourcing and building a global reputation for partnering.
- Patrick Speedie Chief Business Officer @ Inpart
- Nathan Lawless Director of External Innovation @ CSL
- Laurent Jacqueroud Business Development and Investment Director @ Cumulus Oncology
Recording not available.
Modernizing alliance management
This session covers alliance management strategies, balancing human relationships with technical operations.
- Shanker Shrestha Senior Solutions Consultant @ Inpart
- Daniel Goday Sagarra Associate Project Manager - Early Innovation @ Novo Nordisk
- Larissa Eheim Alliance Management Manager @ Genmab
- Julie Settipani Product Manager @ Inpart
Recording not available.
Leveraging advanced partnering data
This session covers alliance management strategies, balancing human relationships with technical operations.
- Echo Zhang VP of Product Strategy @ Inpart
- Rana Houry Product Manager @ Inpart
- Sofia Petta Consultant @ Evaluate Pharma